FindTrial
Sign In

HER2Bi-armed activated T cells

BIOLOGICAL4 trials

Sponsors

Barbara Ann Karmanos Cancer Institute

Conditions

Breast CancerCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMalignant Ovarian Clear Cell TumorMalignant Ovarian Serous TumorPSA ProgressionProstate Carcinoma Metastatic in the BoneRecurrent Fallopian Tube Carcinoma

Phase 1

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
WithdrawnNCT02470559
Barbara Ann Karmanos Cancer InstituteMalignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma +14
Start: 2015-06-30End: 2017-02-28Updated: 2016-02-17

Phase 2

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
TerminatedNCT01022138
Barbara Ann Karmanos Cancer InstituteBreast Cancer
Start: 2010-03-08End: 2019-02-19Updated: 2022-12-23
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
TerminatedNCT01147016
Barbara Ann Karmanos Cancer InstituteBreast Cancer
Start: 2010-07-31End: 2017-07-26Updated: 2023-04-27
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
CompletedNCT03406858
Barbara Ann Karmanos Cancer InstituteCastration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone +2
Start: 2018-06-07End: 2022-11-07Updated: 2023-05-03

Related Papers

Phase II trial of a novel immunotherapy combination of pembrolizumab and HER2 bi-armed activated T cells (BATs) in metastatic castrate resistant prostate cancer.
Journal of Clinical Oncology2020-02-196 citations
Phase II trial evaluating HER2 targeted activated T cells in advanced HER2 low expressing breast cancer patients.
Journal of Clinical Oncology2014-05-201 citations